Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections

Simple item page
dc.contributor.authorKasozi, Keneth Iceland
dc.contributor.authorAlqarni, Mohammed
dc.contributor.authorZirintunda, Gerald
dc.contributor.authorSsempijja, Fred
dc.contributor.authorMusinguzi, Simon Peter
dc.contributor.authorMatama, Kevin
dc.contributor.authorMbiydzenyuy, Ngala Elvis
dc.contributor.authorWelburn, Susan Christina
dc.date.accessioned2022-09-13T16:48:57Z
dc.date.available2022-09-13T16:48:57Z
dc.date.issued2020
dc.description.abstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by severe cytokine storm syndrome following inflammation. SARS-CoV-2 directly interacts with angiotensin-converting enzyme 2 (ACE-2) receptors in the human body. Complementary therapies that impact on expression of IgE and IgG antibodies, including administration of bee venom (BV), have efficacy in the management of arthritis, and Parkinson's disease. A recent epidemiological study in China showed that local beekeepers have a level of immunity against SARS-CoV-2 with and without previous exposure to virus. BV anti-inflammatory properties are associated with melittin and phospholipase A2 (PLA2), both of which show activity against enveloped and non-enveloped viruses, including H1N1 and HIV, with activity mediated through antagonist activity against interleukin-6 (IL-6), IL-8, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α). Melittin is associated with the underexpression of proinflammatory cytokines, including nuclear factor-kappa B (NF-κB), extracellular signal-regulated kinases (ERK1/2), and protein kinase Akt. BV therapy also involves group III secretory phospholipase A2 in the management of respiratory and neurological diseases. BV activation of the cellular and humoral immune systems should be explored for the application of complementary medicine for the management of SARS-CoV-2 infections. BV “vaccination” is used to immunize against cytomegalovirus and can suppress metastases through the PLA2 and phosphatidylinositol-(3,4)-bisphosphate pathways. That BV shows efficacy for HIV and H1NI offers opportunity as a candidate for complementary therapy for protection against SARS-CoV-2.en_US
dc.identifier.citationKasozi, K. I., Niedbała, G., Alqarni, M., Zirintunda, G., Ssempijja, F., Musinguzi, S. P., ... & Welburn, S. C. (2020). Bee venom—a potential complementary medicine candidate for SARS-CoV-2 infections. Frontiers in public health, 8, 594458.https://doi.org/10.3389/fpubh.2020.594458en_US
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/4702
dc.language.isoenen_US
dc.publisherFrontiers in public healthen_US
dc.subjectbee venom, complementary medicine and alternative medicine, SARS-CoV-2 (2019-nCoV), pharmokinetics of bee poison, COVID-19 and complementary medicine, bee venom in clinical trialsen_US
dc.titleBee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infectionsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections.pdf
Size:
799.3 KB
Format:
Adobe Portable Document Format
Description:
Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences